Chugai Pharmaceutical Co., Ltd. (4519) Earnings Call Transcripts

Chugai Pharmaceutical Co., Ltd.'s Latest Earnings Call - Q1 FY2026

In the first quarter of FY 2026, Chugai Pharmaceutical reported revenue of JPY 321.7 billion, an increase of 11.5% year-over-year, and operating profit of JPY 163.3 billion, up 17.1%. The strong performance was primarily driven by robust exports of Hemlibra and NEMLUVIO, alongside increased royalty income. Management maintained their guidance for the fiscal year, indicating that the results were in line with expectations, but did not signal any changes to their forecasts.

Reported metrics

Guidance from management

Management maintained their fiscal year guidance, indicating that the current performance aligns with their expectations. They did not signal any changes to their forecasts despite the strong first quarter results.

What management said

Thank you very much for taking time out of your very busy schedules to attend our first quarter FY 2026 earnings call. My name is Miyata from Corporate Communication and IR Department, and I'll be serving as the moderator today. Thank you for your kind attention. The session will be conducted via Zoom webinar. We will proceed according with the agenda shown on Page 3 of the presentation materials. The briefing will...

We will now move on to the QA session. For QA, Takano, who is the Head of Sales Division, will also join. [Operator Instructions]. So we will now begin taking questions. [Operator Instructions] From Citigroup, Yamaguchi-san.

What analysts pressed on

Analysts expressed concerns regarding the sustainability of the strong performance in the coming quarters, particularly for Hemlibra and NEMLUVIO. There were questions about the potential for fluctuations in sales patterns and the impact of market dynamics on future growth.

Main topics on the call

• Revenue Growth — Chugai's revenue increased by JPY 33.2 billion year-over-year, driven by both domestic and overseas sales. CEO Okuda stated, "Growth was driven mainly by Hemlibra exports to Roche as well as increased NEMLUVIO exports an...
• Product Performance — Domestic sales rose to JPY 111.4 billion, up 8.2% year-over-year, while overseas sales reached JPY 180.1 billion, up 14.9%. The performance of new products and mainstay products offset the negative impacts from NHI drug ...
• Pipeline Developments — Chugai is advancing its pipeline with plans to initiate two Phase III trials for NXT007 in the second quarter and has launched Elevidys, Japan's first gene therapy for DMD. However, development for GYM329 has been discon...
• Cost Management — Operating margin improved to 52.8%, up 2.4 percentage points year-over-year, despite an increase in R&D and SG&A expenses. CFO Taniguchi noted, "SG&A is expected to trend lower year-on-year from the second quarter onward...

Read the full Chugai Pharmaceutical Co., Ltd. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 21 Chugai Pharmaceutical Co., Ltd. earnings call transcripts on record, spanning January 31, 2020 to July 24, 2026. Based on this history, Chugai Pharmaceutical Co., Ltd. reports semi-annually. The most recent call on file is dated July 24, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

4519

Exchange

TSE

Country

JP

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

21

First call

January 31, 2020

Most recent

July 24, 2026

Reporting cadence

semi-annually